Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Anti-CD38 mAb (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human CD38, His Tag (Cat. No. CD8-H5224) with an affinity constant of 4.98 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Daratumumab/Hyaluronidase-fihj | Approved | Johnson & Johnson Innovative Medicine | Darzalex Faspro, Darzquro | United States | Multiple Myeloma | Janssen Biotech Inc | 2020-05-01 | Monoclonal Gammopathy of Undetermined Significance; Rejection in heart transplantation; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Myeloid, Acute; Primary Myelofibrosis; Amyloidosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Anemia, Aplastic; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Hematologic Neoplasms; Multiple Myeloma; Myelodysplastic Syndromes; Hodgkin Disease; Smoldering Multiple Myeloma; Immunoglobulin Light-chain Amyloidosis; Peripheral Nervous System Diseases; Leukemia, Myelogenous, Chronic; Bone marrow transplant rejection | Details | |
| Isatuximab | SAR-650984; hu38SB19 | Approved | Immunogen Inc | Sarclisa | United States | Multiple Myeloma | Sanofi-Aventis U.S. Llc | 2020-03-02 | Satiety Response; Carcinoma, Non-Small-Cell Lung; Leukemia, T-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Macroglossia; Leukemia, Myeloid, Acute; Nausea; Amyloidosis; Hepatomegaly; Anemia, Aplastic; Anemia, Hemolytic, Autoimmune; Gastrointestinal Hemorrhage; Diarrhea; Prostatic Neoplasms; Goiter, Nodular; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Multiple Myeloma; Hodgkin Disease; Neoplasms; Purpura; Leukemia, Plasma Cell; Immunoglobulin Light-chain Amyloidosis; Smoldering Multiple Myeloma; Lymphadenopathy; Paraproteinemias; Hematologic Neoplasms; Constipation | Details |
| Daratumumab | JNJ-54767414 | Approved | Johnson & Johnson Innovative Medicine | Darzalex, 兆珂速, 兆珂 | United States | Multiple Myeloma | Janssen Biotech Inc | 2015-11-16 | Rejection of organ transplantation; Hypersensitivity; POEMS Syndrome; Waldenstrom Macroglobulinemia; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Lymphoma; Alzheimer Disease; Urologic Neoplasms; Amyloidosis; Lymphoma, Primary Effusion; Lupus Erythematosus, Systemic; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Prostatic Neoplasms; Purpura, Thrombocytopenic, Idiopathic; Multiple Myeloma; Carcinoma, Transitional Cell; Autoimmune Diseases; Hodgkin Disease; Glioblastoma; Immunoglobulin Light-chain Amyloidosis; Lymphoma, Large B-Cell, Diffuse; Myelodysplastic Syndromes; Smoldering Multiple Myeloma; Carcinoma, Renal Cell; Paraproteinemias; Genital Neoplasms, Male; Rejection of renal transplantation; Kidney Neoplasms | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Mezagitamab | TAK-079 | Phase 3 Clinical | Takeda | Purpura, Thrombocytopenic, Idiopathic; Hematologic Neoplasms; Myasthenia Gravis; Nephrosis; Glomerulonephritis, IGA; Kidney Diseases; Autoimmune Diseases; Multiple Myeloma; Lupus Erythematosus, Systemic; Thrombocytopenia; Glomerulonephritis | Details |
| Daratumumab biosimilar (Biocad) | BCD-264 | Phase 3 Clinical | BIOCAD JSC | Multiple Myeloma | Details |
| Recombinant human anti-CD38 momoclonal antibody(Sumgen) | SG-301; SG301 | Phase 3 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Hematologic Neoplasms; Multiple Myeloma; Lupus Erythematosus, Systemic | Details |
| STI-6129 | STI-6129; LNDS-1001 | Phase 2 Clinical | Sorrento Therapeutics Inc | Solid tumours; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
| Modakafusp alfa | TEV-48573; TAK-573 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd | Neoplasms; Multiple Myeloma; Melanoma | Details |
| 4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-T | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Hematologic Neoplasms; Autoimmune Diseases; Neuroblastoma | Details |
| REGN-7945 | REGN7945; REGN-7945 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Multiple Myeloma | Details |
| SCTC-21-C | SCTC21C; SCTC-21-C; SCT-C21C | Phase 2 Clinical | SinoCelltech Ltd | Hematologic Neoplasms; Glomerulonephritis, IGA; Autoimmune Diseases | Details |
| Anti-CD38 Antibody(Institute of Hematology & Blood Diseases Hospital) | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | Purpura, Thrombocytopenic, Idiopathic; Antiphospholipid Syndrome; Thrombocytopenia | Details | |
| Erzotabart | GEN-3014 | Phase 2 Clinical | Genmab A/S | Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Leukemia, Myeloid, Acute | Details |
| CID-103 | CID-103; TSK011010 | Phase 2 Clinical | Tusk Therapeutics Ltd | Purpura, Thrombocytopenic, Idiopathic; Multiple Myeloma; Thrombocytopenia | Details |
| BHV-1100 | KP-1237; BHV-1100 | Phase 2 Clinical | PeptiDream Inc, Biohaven Pharmaceuticals Inc, Kleo Pharmaceuticals | Multiple Myeloma | Details |
| Lumrotatug | CM-313 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Purpura, Thrombocytopenic, Idiopathic; Hematologic Neoplasms; Glomerulonephritis, IGA; Multiple Myeloma; Lupus Erythematosus, Systemic; Anemia, Aplastic; Lymphoma; Thrombocytopenia | Details |
| 89Zr-DFO-daratumumab | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center | Multiple Myeloma | Details | |
| 64Cu-DOTA-daratumumab | Phase 1 Clinical | City Of Hope National Medical Center | Multiple Myeloma | Details | |
| SAR-442257 | SAR-442257 | Phase 1 Clinical | Sanofi | Neoplasms | Details |
| Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) | Phase 1 Clinical | Shengyan Pharmaceutical Technology | Multiple Myeloma | Details | |
| T-007 (TNK Therapeutics/Celularity) | Phase 1 Clinical | Tnk Therapeutics Inc | Multiple Myeloma | Details | |
| Anti-CD38 chimeric antigen receptor T cell therapy(Yake Biotechnology) | CAR-T CD-38 | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma; Leukemia, Myeloid, Acute | Details |
| Phase 1 Clinical | The Second Hospital Of Shandong University | Multiple Myeloma | Details | ||
| SAR-444559 | SAR444559; SAR-444559 | Phase 1 Clinical | Sanofi | Inflammation | Details |
| 68Ga-NB-381 | 68Ga-NB381; 68Ga-NB-381; 18F-FDG(The First Affiliated Hospital Of Beijing University) | Phase 1 Clinical | The First Affiliated Hospital Of Beijing University | Multiple Myeloma | Details |
| CLL1 and CD38 Dual CAR-T therapy(Gracell Biotechnologies) | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Leukemia, Myeloid, Acute | Details | |
| Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, Myeloid, Acute | Details | |
| CD38-SADA:177 Lu-DOTA Drug Complex | Phase 1 Clinical | Y-Mabs Therapeutics Inc | Lymphoma, Non-Hodgkin | Details | |
| Daratumumab biosimilar (Hangzhou Jiuyuan Gene Engineering) | Phase 1 Clinical | Hangzhou Jiuyuan Gene Engineering Co., Ltd. | Multiple Myeloma | Details | |
| Daratumumab biosimilar (Chiatai Tianqing) | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Multiple Myeloma | Details | |
| CART-38（University of Pennsylvania） | CART-38 | Phase 1 Clinical | University Of Pennsylvania | Multiple Myeloma; Leukemia, Myeloid, Acute | Details |
| ISB-2001 | ISB-2001 | Phase 1 Clinical | Ichnos Sciences Sa | Multiple Myeloma | Details |
| TNB-738 | TNB-738 | Phase 1 Clinical | TeneoFour Inc | Details | |
| GBR-1342 | GBR-1342; ISB-1342 | Phase 1 Clinical | Glenmark Pharmaceuticals Ltd | Multiple Myeloma | Details |
| XmAb-968 | XmAb968 | Phase 1 Clinical | Xencor Inc | Hematologic Neoplasms; Leukemia, Promyelocytic, Acute | Details |
| SG-2501 | SG-2501 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Hematologic Neoplasms; Lymphoma | Details |
| XmAb-18968 | XmAb-18968 | Phase 1 Clinical | The Medical College Of Wisconsin Nonprofit | Leukemia, Myeloid, Acute | Details |
| Daratumumab biosimilar (Henlius) | HLX-15 | Phase 1 Clinical | Shanghai Henlius Biologics Co Ltd | Multiple Myeloma | Details |
| 211At-OKT10-B10 | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | Multiple Myeloma | Details | |
| Y-150(Wuhan Yzy Biopharma/CSPC Pharmaceutical) | Y-150; Y150 | Phase 1 Clinical | Wuhan Yzy Biopharma Co Ltd, CSPC Pharmaceutical Group Ltd | Multiple Myeloma | Details |
| Anti CD38 chimeric antigen receptor T-cell therapy (Sorrento Therapeutics) | Phase 1 Clinical | Celularity Inc, Sorrento Therapeutics Inc | Multiple Myeloma | Details | |
| SAR-442085 | SAR-442085 | Phase 1 Clinical | Sanofi | Multiple Myeloma | Details |
| KJ-C2320 | KJ-C2320 | Clinical | CARsgen Therapeutics Holdings Ltd | Leukemia, Myeloid, Acute | Details |
This web search service is supported by Google Inc.
A-Z
